Status:
NOT_YET_RECRUITING
Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Breast Cancer
Eligibility:
All Genders
18-90 years
Brief Summary
This study is designed to evaluate the effect of using the application on the adherence of patients with luminal HER2- breast cancer (BC) stage II-III to adjuvant therapy with ribociclib in combinatio...
Eligibility Criteria
Inclusion
- Female and male patients with histologically verified and radically treated stage II-III hormone receptor positive HER2-negative breast cancer;
- Age ≥ 18 at the time of initiation of ribociclib therapy;
- Patients who were prescribed ribociclib + AI (±GnRH agonist for premenopausal men and women) not earlier than 28 days before signing the informed consent;
- It is allowed to start adjuvant hormone therapy with AI (±GnRH agonist) not earlier than 12 months before the start of ribociclib;
- Provision of written informed consent.
Exclusion
- Patients participating in any interventional clinical study at the time of signing the informed consent;
- Patients receiving active treatment for malignant neoplasms other than BC at the time of enrollment.
Key Trial Info
Start Date :
July 31 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2029
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT06905301
Start Date
July 31 2025
End Date
July 1 2029
Last Update
April 1 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.